Actualités et Activités de Repertoire Immune Medicines

Voir l'organigramme avec ses 17 principaux dirigeants

Biographies les plus recherchées chez Repertoire Immune Medicines

• Torben Nissen, Chief Executive Officer
• Doug Cole, Director
• JC Gutierrez-Ramos, Director

Créer une alerte
pour suivre les mouvements de dirigeants chez Repertoire Immune Medicines.

Repertoire Immune Medicines a 2 405 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Vertex Pharmaceuticals (Etats—Unis).

Actualités en fusion/acquisition en Biotechnologie.

• Ona Therapeutics vient d'annoncer une levée de fonds de 87 millions de dollars. (publié le 5 juin 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publié le 4 juin 2026).
• Oak Hill Bio vient d'annoncer une levée de fonds de 33 millions de dollars. (publié le 4 juin 2026).

Contacts en Biotechnologie

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer chez Inceptive
• Jan Van de Winkel - President and Chief Executive Officer chez Genmab
• Carl Gordon - Director chez Odyssey Therapeutics

En savoir plus sur le secteur Biotechnologie

Derniers communiqués de presse par Repertoire Immune Medicines

• Repertoire® Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201 • Repertoire Immune Medicines
• Repertoire® Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors • Repertoire Immune Medicines
• Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases • Repertoire Immune Medicines
• Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer • Repertoire Immune Medicines
• Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic • Repertoire Immune Medicines
• Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease • Repertoire Immune Medicines
• Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • Repertoire Immune Medicines
• Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics • Repertoire Immune Medicines
• Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer • Repertoire Immune Medicines
• New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer • Repertoire Immune Medicines
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de Repertoire Immune Medicines

• Repertoire Immune Medicines sur Wikipédia, Google News & Yahoo Finance en 1-click
• Repertoire Immune Medicines sur LinkedIn, X (Twitter) & YouTube en 1-click